Pfizer's Experimental Anti-cholesterol Treatment Meets Main Study Goals
28 March 2014 - 12:00AM
Dow Jones News
By Tess Stynes
Pfizer Inc. (PFE) said its experimental anti-cholesterol
treatment significantly reduced LDL-C cholesterol across several
dosing levels in a Phase 2b study of patients at high risk for
cardiovascular events.
Bococizumab--also known as RN316--is part of a class of
treatments called PCSK9 inhibitors, which are being developed by
several major drug companies. Analysts and investors have watched
development of the drugs closely because of their potential to
treat millions of patients whose high cholesterol isn't well
controlled with statins.
The study included statin-treated patients with high cholesterol
who received doses of either bococizumab twice or once monthly
subcutaneous administration or placebo. The study met its primary
endpoint across all doses, Pfizer said.
Elevated LDL-C is recognized as a major risk factor for
cardiovascular disease.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024